ADCC-Enhanced Anti-Human PD-1 (Penpulimab) Antibody (CAT#: BioBet-CB-039LX) Datasheet

Programmed cell death protein 1

Programmed cell death protein 1

Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers. PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.

PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Penpulimab

Humanized

Human

ADCC-Enhanced Anti-Human PD-1 (Penpulimab) Antibody is derived from clone Penpulimab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the PD-1, and it is intended for the research of Non-small cell lung cancer .

Non-small cell lung cancer